FREQUENCY AND COST OF DISABILITY AMONG EMPLOYED INDIVIDUALS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Author(s)
Theodore Darkow, PharmD, Researcher1, Pamela J. Kadlubek, MPH, Senior Research Analyst1, Hemal Shah, PharmD, Director2, Amy L. Phillips, PharmD, Manager2, Jeno P. Martön, MD, Director31i3 Magnifi, An Ingenix Company, Eden Prairie, MN, USA; 2 Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA; 3 Pfizer Pharmaceuticals Group, Pfizer Inc, New York, NY, USA
OBJECTIVES: Examine frequency and costs of disability among employed individuals with COPD. METHODS: Retrospective analysis of disability and medical claims data for employees of nine national self-insured companies. Active employees 40-63 years old with diagnosis of COPD (ICD-9-CM: 491.xx,492.x,496) between January 1, 2001 - December 31, 2003 were identified. Index date was later of: 1) first COPD diagnosis, or 2) first date of eligibility for short-term disability (STD), long-term disability (LTD), and health benefits. Employees with cystic fibrosis, lung cancer, tuberculosis, or pregnancy, and those continuously eligible for <90 days following index date, were excluded. Using propensity score matching, controls were matched 2:1 to COPD subjects on age, gender, geographic region, employer, length of employment, and salary range. Subjects were followed until the earliest of non-active employee status, disenrollment from any benefit, 365 days of follow-up, or March 31, 2004. Likelihood of disability was compared between COPD subjects and controls using logistic regression, adjusting for length of follow-up and specific comorbidities. Indirect costs of disability, measured as disability days multiplied by subjects' daily wage, were compared among subjects with a disability claim using GLM with a gamma distribution and log link, adjusting by the aforementioned covariates. RESULTS: Mean length of follow-up for COPD subjects (n=1349) and controls (n=2696) was 220 and 233 days. Mean age was 52 years, and cohorts approximately 50% male. All comorbidities were more common in the COPD cohort. A greater proportion of COPD subjects used STD (21.8% vs. 7.0%), LTD (2.4% vs. 0.4%), or any disability benefit (22.8% vs. 7.3%). Odds ratios for likelihood of disability for COPD subjects were: STD, 2.11 (95% CI: 1.64-2.71); LTD, 4.21 (1.93-9.16); any disability, 2.15 (1.68-2.75). CONCLUSIONS: Among those with disability (307 COPD patients, 197 controls), indirect costs were higher among COPD subjects ($8559) than controls ($5443); this approached significance (p=0.07).
Conference/Value in Health Info
2006-05, ISPOR 2006, Philadelphia, PA
Value in Health, Vol. 9, No.3 (May/June 2006)
Code
CS4
Topic
Economic Evaluation
Topic Subcategory
Work & Home Productivity - Indirect Costs
Disease
Respiratory-Related Disorders